Navigation Links
Mylan Announces Appointment of Harry A. Korman as President, North America
Date:10/2/2007

PITTSBURGH, Oct. 2 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced the appointment of Harry A. (Hal) Korman to the position of President, North America following the completion of the acquisition of Merck Generics Group today.

In his new role, Mr. Korman will continue to drive growth and development of Mylan Pharmaceuticals Inc. (MPI), Mylan's generics business in the U.S. In addition, he will oversee GenPharm, Inc., the former Canadian subsidiary of Merck Generics and the fourth largest generics company in Canada, and UDL Laboratories, Inc., the U.S. leader in unit dose packaging.

Mr. Korman previously served as President of MPI, as well as Senior Vice President of Mylan Laboratories Inc. Since joining Mylan through its acquisition of UDL Laboratories in 1996, he has served the Company in several capacities of increasing responsibility, including President of UDL and Vice President of Sales and Marketing for MPI.

Mylan Vice Chairman and CEO Robert J. Coury commented: "Hal has played a critical role in our success to date and is a key member of our management team. He has been instrumental in building Mylan into the leader in quality generics in the U.S. that we are today. Since Hal's appointment as President of MPI, he has proven his ability to meet or exceed every objective set for him and he will certainly rise to these new responsibilities. By bringing these North American businesses together under Hal's leadership, we will be best placed to identify and execute on growth and synergy opportunities in the region. I am confident that we will continue to go from strength to strength in North America."

Mr. Korman said: "It's been an honor to be part of Mylan for the last 20 years as the company has grown from a leader in the U.S. to a new global leader in generics and specialty pharmaceuticals. I am also proud to be part of a management team that truly shares one vision for the new Mylan. As we look ahead to the future, there have never been greater opportunities to take the company forward and continue to provide the best quality products and service to our customers."

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Wins Its Amlodipine Case With Pfizer
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Mylan Announces Final FDA Approval for Fluoxetine Capsules
4. PM announces a new health care order for India
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. PowderMed Announces Needle-Less Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Reflections Recovery ... now accredited by The Joint Commission for chemical dependency and behavioral health services. ... U.S. health care organizations that meet the commission’s rigorous standards. Accreditation by The ...
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ... (CoE) with the latest Artificial Intelligence (AI) thinking, announced today the launch of ... easy access to essential information that offers a more comprehensive understanding of the ...
(Date:9/20/2017)... Ashburn, Virginia (PRWEB) , ... September 20, 2017 ... ... Spartacote Flex Pure Clinical Plus Coating System for clients that rely on safety ... inhibit the growth of microorganisms. , Silver has been used for centuries for ...
(Date:9/20/2017)... ... September 20, 2017 , ... On ... Best Places to Work in the Research Triangle for 2017. , Winners were ... company had to meet a threshold in employee participation--a percentage that varies based ...
(Date:9/20/2017)... ... September 20, 2017 , ... Renal Support Network’s annual essay ... kidney disease. The theme “Describe a positive decision that you have made about ... meet only one qualification— to have been diagnosed with chronic kidney disease. This ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , ... Allentown, Penn. , and OptiMed Specialty Pharmacy of ... business partnership to offer a strategic hub service that ... Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, and ... A spirometer is a medical device used to ...
Breaking Medicine Technology: